Literature DB >> 26553018

Role of blood transfusion product type and amount in deep vein thrombosis after cardiac surgery.

Lama Ghazi1, Thomas A Schwann2, Milo C Engoren3, Robert H Habib4.   

Abstract

BACKGROUND: Postoperative deep vein thrombosis (DVT) is associated with significant morbidity. Even with maximal thromboprophylaxis, postoperative DVT is present in 10% of cardiac surgery patients, and is linked to receiving transfusion. We hypothesized that the incidence of DVT varies with the transfused blood product type, and increases with transfusion dose. STUDY DESIGN AND METHODS: 139/1070 cardiac surgery patients have DVT despite maximal chemo and mechanical prophylaxis. DVTs were detected via serial perioperative duplex venous scans (DVS). Red blood cells (RBC), platelets (PLT), plasma (FFP) and cryoprecipitate transfusion data were collected.
RESULTS: Transfusion was used in 506(47%) patients: RBC [468(44%); 4.0 ± 4.2u]; FFP [155(14.5%); 3.5 ± 2.3 u]; PLT [185(17.3%); 2.2 ± 1.3 u] and Cryoprecipitate [51(4.8%); 1.3 ± 0.6 u]. Isolated RBC transfusion accounted for 92.6% patients receiving one product, and their DVT rate was increased considerably compared to no transfusion (16.7% versus 7.3%; P<0.001). Incidence of DVT increased substantially for multiple product transfusions; particularly when both RBC and FFP are used (25%-40%). Relative to no RBC (n=602), multivariate logistic regression analysis identified a significant RBC-DVT dose dependent relation (P<0.001) with: 1-3 RBC units [n=285, AOR=1.95(1.23-3.07), adjusted odds ratio (95% confidence interval)]; 4-6 units [n=117; AOR=1.65(0.86-3.20)]; and ≥ 7 RBC units [n=66; 3.19(1.52-6.70)]. This relation also increased according to an RBC∗FFP interaction term [AOR=1.87(1.11-3.22); P=0.022].
CONCLUSION: RBC transfusion is associated with increased risk of DVT after cardiac surgery in a dose-dependent fashion that is exacerbated when accompanied with FFP. Postoperative screening diagnostic DVS are warranted in this transfused, high risk for DVT population to facilitate timely therapeutic intervention.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blood transfusion; Cardiac surgery; Deep vein thrombosis

Mesh:

Year:  2015        PMID: 26553018     DOI: 10.1016/j.thromres.2015.10.041

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

Review 1.  Impact of drugs on venous thromboembolism risk in surgical patients.

Authors:  Alenka Premuš Marušič Kovačič; Martin Caprnda; Aleš Mrhar; Peter Kubatka; Igor Locatelli; Barbora Zolakova; Ludovit Gaspar; Robert Prosecky; Peter Kruzliak; Robert Staffa; Luis Rodrigo; Jozef Radonak; Danijel Petrovič
Journal:  Eur J Clin Pharmacol       Date:  2019-02-05       Impact factor: 2.953

2.  Perioperative Transfusions and Venous Thromboembolism.

Authors:  Ruchika Goel; Cassandra D Josephson; Eshan U Patel; Molly R Petersen; Sarah Makhani; Steven M Frank; Paul M Ness; Evan M Bloch; Eric A Gehrie; Parvez M Lokhandwala; Marianne M Nellis; Oliver Karam; Beth H Shaz; Ravi M Patel; Aaron A R Tobian
Journal:  Pediatrics       Date:  2020-03-20       Impact factor: 7.124

3.  Intra-operative blood transfusion significantly increases the risk of post-operative pulmonary embolism.

Authors:  Qiaojun Zeng; Shufang Tan; Qiang Bao; Shanping Jiang
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

4.  Incidence of proximal deep vein thrombosis in medical critical care patients.

Authors:  Chairat Permpikul; Walailak Chaiyasoot; Anupol Panitchote
Journal:  Thromb J       Date:  2022-02-05

5.  Effect of red blood cell transfusion on inflammation, endothelial cell activation and coagulation in the critically ill.

Authors:  Lisa van Manen; Maike E van Hezel; Margit Boshuizen; Marleen Straat; Angelique M E de Man; Charlotte Dekimpe; Karen Vanhoorelbeke; Robin van Bruggen; Nicole P Juffermans
Journal:  Vox Sang       Date:  2021-07-01       Impact factor: 2.996

Review 6.  Interplay between platelets and coagulation.

Authors:  Yaqiu Sang; Mark Roest; Bas de Laat; Philip G de Groot; Dana Huskens
Journal:  Blood Rev       Date:  2020-07-12       Impact factor: 10.626

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.